MAF1 inhibits hepatocarcinogenesis by fostering an immunostimulatory tumor microenvironment
Our study uncovers a novel anti-tumor immunity of MAF1 in hepatocarcinogenesis and human HCC. These findings suggest that the stimulated MAF1 could potentially improve immunotherapy in combination with immune checkpoint inhibitors in HCC patients, especially in those with an absence of T cells in HCC tissues.
Authors
- Haojiang Li (ORCID: https://orcid.org/0000-0001-5854-3989)
- Yufeng Zhou (ORCID: https://orcid.org/0000-0002-6050-4951)
- Shi‐Juan Mai (ORCID: https://orcid.org/0000-0003-0017-8194)
- Ge Ren (ORCID: https://orcid.org/0000-0003-2049-2682)
- Shuo-Cheng Wang
- Hui‐Yun Wang (ORCID: https://orcid.org/0000-0001-6728-4376)
- Yue-Ning Wang
- Di Cao (ORCID: https://orcid.org/0000-0001-7406-8938)
- Chao‐Yue Sun
- Mei-Yin Zhang
Institutions
- Hong Kong Polytechnic University (HK)
- Sun Yat-sen University (CN)
- Sun Yat-sen University Cancer Center (CN)
- West Anhui University (CN)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1136/jitc-2024-009656
- Primary Topic
- RNA modifications and cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China